An EUA for molnupiravir was granted on December 23, 2021 for treatment of mild- to- moderate COVID- 19 in adults aged 18 years and older who test positive for SARS- CoV- 2 virus, and are at high risk for progression to severe COVID- 19, including hospitalization or death.

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت

According to Kocbach et al.